Trial Profile
Chidamide Plus Post-transplantation Cyclophosphamide and Cyclosporine to Prevent Graft-versus-host Disease After Myeloablative Conditioning, Matched Peripheral-blood Stem-cell Transplantation
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary) ; Ciclosporin; Ciclosporin; Cyclophosphamide
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 17 Jul 2018 Planned initiation date changed from 1 Jan 2018 to 1 Jan 2019.
- 14 Nov 2017 New trial record